Estrogen receptor α (ERα) mediates 17β-estradiol (E2)-activated expression of HBO1
Tóm tắt
HBO1 (histone acetyltransferase binding to ORC1) is a histone acetyltransferase (HAT) which could exert oncogenic function in breast cancer. However, the biological role and underlying mechanism of HBO1 in breast cancer remains largely unknown. In the current study, we aimed to investigate the role of HBO1 in breast cancer and uncover the underlying molecular mechanism. Immunohistochemistry was applied to detect HBO1 protein expression in breast cancer specimens (n = 112). The expression of protein level was scored by integral optical density (IOD) for further statistical analyses using SPSS. Real-time PCR was used to simultaneously measure mRNA levels of HBO1. The HBO1 protein expression in breast cancer cells was confirmed by western blot. HBO1 was highly expressed in breast cancer tissues and significantly correlated with estrogen receptor α (ERα) (p < 0.001) and progestational hormone (PR) (p = 0.002). HBO1 protein level also correlated positively with histology grade in ERα positive tumors (p = 0.016) rather than ERα negative tumors. 17β-estradiol (E2) could upregulate HBO1 gene expression which was significantly inhibited by ICI 182,780 or ERα RNAi. E2-increased HBO1 protein expression was significantly suppressed by treatment with inhibitor of MEK1/2 (U0126) in T47 D and MCF-7 cells. HBO1 was an important downstream molecule of ERα, and ERK1/2 signaling pathway may involved in the expression of HBO1 increased by E2.
Tài liệu tham khảo
Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 2005, 55: 74-108. 10.3322/canjclin.55.2.74.
Liao DZ, Pantazis CG, Hou X, Li SA: Promotion of estrogen-induced mammary gland carcinogenesis by androgen in the male Noble rat: probable mediation by steroid receptors. Carcinogenesis. 1998, 19: 2173-80. 10.1093/carcin/19.12.2173.
Pettersson K, Gustafsson JA: Role of estrogen receptor beta in estrogen action. Annu Rev Physiol. 2001, 63: 165-92. 10.1146/annurev.physiol.63.1.165.
Hilakivi-Clarke L, Cho E, Cabanes A, et al: Dietary modulation of pregnancy estrogen levels and breast cancer risk among female rat offspring. Clin Cancer Res. 2002, 8: 3601-10.
Clarke R, Liu MC, Bouker KB, et al: Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene. 2003, 22: 7316-39. 10.1038/sj.onc.1206937.
O'Lone R, Frith MC, Karlsson EK, Hansen U: Genomic targets of nuclear estrogen receptors. Mol Endocrinol. 2004, 18: 1859-75. 10.1210/me.2003-0044.
Iizuka M, Takahashi Y, Mizzen CA, et al: Histone acetyltransferase Hbo1: catalytic activity, cellular abundance, and links to primary cancers. Gene. 2009, 436: 108-14. 10.1016/j.gene.2009.01.020.
Hu X, Stern HM, Ge L, et al: Genetic alterations and oncogenic pathways associated with breast cancer subtypes. Mol Cancer Res. 2009, 7: 511-22. 10.1158/1541-7786.MCR-08-0107.
Georgiakaki M, Chabbert-Buffet N, Dasen B, et al: Ligand-controlled interaction of histone acetyltransferase binding to ORC-1 (HBO1) with the N-terminal transactivating domain of progesterone receptor induces steroid receptor coactivator 1-dependent coactivation of transcription. Mol Endocrinol. 2006, 20: 2122-40. 10.1210/me.2005-0149.
Wang Y, Zong H, Chi Y, et al: Repression of estrogen receptor alpha by CDK11p58 through promoting its ubiquitin-proteasome degradation. J Biochem. 2009, 145: 331-43. 10.1093/jb/mvn177.
Remmele W, Stegner HE: Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe. 1987, 8: 138-40.
MacGregor JI, Jordan VC: Basic guide to the mechanisms of antiestrogen action. Pharmacol Rev. 1998, 50: 151-96.
Wakeling AE: Similarities and distinctions in the mode of action of different classes of antioestrogens. Endocr Relat Cancer. 2000, 7: 17-28. 10.1677/erc.0.0070017.
Clark J, Edwards S, John M, et al: Identification of amplified and expressed genes in breast cancer by comparative hybridization onto microarrays of randomly selected cDNA clones. Genes Chromosomes Cancer. 2002, 34: 104-14. 10.1002/gcc.10039.
Hyman E, Kauraniemi P, Hautaniemi S, et al: Impact of DNA amplification on gene expression patterns in breast cancer. Cancer Res. 2002, 62: 6240-5.
Pollack JR, Sorlie T, Perou CM, et al: Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc Natl Acad Sci USA. 2002, 99: 12963-8. 10.1073/pnas.162471999.
Miotto B, Struhl K: HBO1 histone acetylase is a coactivator of the replication licensing factor Cdt1. Genes Dev. 2008, 22: 2633-8. 10.1101/gad.1674108.
Yager JD, Davidson NE: Estrogen carcinogenesis in breast cancer. N Engl J Med. 2006, 354: 270-82. 10.1056/NEJMra050776.
Stabile LP, Siegfried JM: Estrogen receptor pathways in lung cancer. Curr Oncol Rep. 2004, 6: 259-67. 10.1007/s11912-004-0033-2.
Marquez-Garban DC, Chen HW, Fishbein MC, Goodglick L, Pietras RJ: Estrogen receptor signaling pathways in human non-small cell lung cancer. Steroids. 2007, 72: 135-43. 10.1016/j.steroids.2006.11.019.
Huss JM, Kelly DP: Nuclear receptor signaling and cardiac energetics. Circ Res. 2004, 95: 568-78. 10.1161/01.RES.0000141774.29937.e3.
Meyer MR, Haas E, Barton M: Gender differences of cardiovascular disease: new perspectives for estrogen receptor signaling. Hypertension. 2006, 47: 1019-26. 10.1161/01.HYP.0000223064.62762.0b.
Atanaskova N, Keshamouni VG, Krueger JS, Schwartz JA, Miller F, Reddy KB: MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance. Oncogene. 2002, 21: 4000-8. 10.1038/sj.onc.1205506.
Martin LA, Farmer I, Johnston SR, Ali S, Dowsett M: Elevated ERK1/ERK2/estrogen receptor cross-talk enhances estrogen-mediated signaling during long-term estrogen deprivation. Endocr Relat Cancer. 2005, 12 (Suppl 1): S75-84. 10.1677/erc.1.01023.
Santen RJ, Song RX, McPherson R, et al: The role of mitogen-activated protein (MAP) kinase in breast cancer. J Steroid Biochem Mol Biol. 2002, 80: 239-56. 10.1016/S0960-0760(01)00189-3.
Migliaccio A, Pagano M, Auricchio F: Immediate and transient stimulation of protein tyrosine phosphorylation by estradiol in MCF-7 cells. Oncogene. 1993, 8: 2183-91.
Auricchio A, di Domenico M, Castoria G, Bilancio A, Migliaccio A: Epidermal growth factor induces protein tyrosine phosphorylation and association of p190 with ras-GTP-ase activating protein in Caco-2 cells. FEBS Lett. 1994, 353: 16-20. 10.1016/0014-5793(94)00987-2.
Auricchio F, Migliaccio A, Castoria G, Di Domenico M, Bilancio A, Rotondi A: Protein tyrosine phosphorylation and estradiol action. Ann N Y Acad Sci. 1996, 784: 149-72. 10.1111/j.1749-6632.1996.tb16234.x.
Migliaccio A, Piccolo D, Castoria G, et al: Activation of the Src/p21ras/Erk pathway by progesterone receptor via cross-talk with estrogen receptor. EMBO J. 1998, 17: 2008-18. 10.1093/emboj/17.7.2008.